Characteristics of patients with PV and ET
| . | PV . | ET . |
|---|---|---|
| N | 30 | 51 |
| Sex (M/F) | 20/10 | 27/24 |
| Median age, y (range) | 64 (43-88) | 64 (36-89) |
| JAK2 mutation (positive/wild-type) | 27/3 | 38/13 |
| Aspirin treatment, n (%) | 30 (100) | 51 (100) |
| Hydroxyurea treatment, n (%) | 20 (71) | 36 (77) |
| History of thrombosis, n (%) | 9 (30) | 12 (23.5) |
| . | PV . | ET . |
|---|---|---|
| N | 30 | 51 |
| Sex (M/F) | 20/10 | 27/24 |
| Median age, y (range) | 64 (43-88) | 64 (36-89) |
| JAK2 mutation (positive/wild-type) | 27/3 | 38/13 |
| Aspirin treatment, n (%) | 30 (100) | 51 (100) |
| Hydroxyurea treatment, n (%) | 20 (71) | 36 (77) |
| History of thrombosis, n (%) | 9 (30) | 12 (23.5) |